Wang JL, Xiang BX, Song XL, Que RM, Zuo XC, Xie YL. Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: A meta-analysis. World J Clin Cases 2022; 10(31): 11466-11485 [PMID: 36387815 DOI: 10.12998/wjcc.v10.i31.11466]
Corresponding Author of This Article
Yue-Liang Xie, PharmD, Pharmacist, Department of Pharmacy, The Third Xiangya Hospital of Central South University, No. 138 Tongzipo Road, Changsha 410013, Hunan Province, China. xieyliang@csu.edu.cn
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jiang-Lin Wang, Bi-Xiao Xiang, Rui-Man Que, Xiao-Cong Zuo, Yue-Liang Xie, Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China
Xiao-Li Song, Department of Pharmacy, Sanya Central Hospital, Sanya 572000, Hainan Province, China
Author contributions: Wang JL acquisition of data, analysis and interpretation of data, drafting the article, final approval; Xiang BX acquisition of data, final approval; Song XL acquisition of data, final approval; Que RM acquisition of data, final approval; Zuo XC critical revision, final approval; Xie YL conception and design of the study, critical revision, final approval.
Supported byThe Hunan Province Natural Science Foundation, No. 2022JJ80043; Nature Science Foundation of Changsha, No. kq2014268; Hunan Engineering Research Center of Intelligent Prevention and Control for Drug Induced Organ Injury, No. 40; Scientific Research Fund Project of Hunan Pharmaceutical Society, No. 2020YXH010.
Conflict-of-interest statement: All the authors declare having no conflict of interest related to this work.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist in detail, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yue-Liang Xie, PharmD, Pharmacist, Department of Pharmacy, The Third Xiangya Hospital of Central South University, No. 138 Tongzipo Road, Changsha 410013, Hunan Province, China. xieyliang@csu.edu.cn
Received: August 8, 2022 Peer-review started: August 8, 2022 First decision: September 5, 2022 Revised: September 15, 2022 Accepted: September 23, 2022 Article in press: September 23, 2022 Published online: November 6, 2022 Processing time: 79 Days and 21.5 Hours
Core Tip
Core Tip: Polymyxins have recently been reintroduced as a last-line option in chemotherapy for infections caused by multidrug-resistant gram-negative bacteria. However, these agents can cause nephrotoxicity. Notably, the prevalence of and risk factors for polymyxin-associated nephrotoxicity in adult intensive care unit (ICU) patients remain unclear. This is the first systematic review and meta-analysis to estimate the prevalence of and risk factors for polymyxin-induced nephrotoxicity in adult ICU patients. Based on the data collected and analysed, we conclude that the high incidence of polymyxin-induced nephrotoxicity is a primary safety concern and challenge in clinical practice. The avoidance of modifiable risk factors (such as nephrotoxic drugs and dosage regimens containing polymyxins) in adult ICU patients can likely reduce the risk of polymyxin-induced nephrotoxicity.
